Edison’s mission is to develop drugs for rare inherited mitochondrial diseases that primarily affect children, and to leverage information gained from the study of these orphan diseases to discover and develop new treatments for other mitochondrial and neurodegenerative diseases with shared mechanisms.
A dedicated group of physicians, researchers, foundations, executives and parents of children with mitochondrial disease founded Edison in 2005. This group understood that breakthroughs occurring in university settings needed to be translated into therapeutics by a company dedicated to rare childhood diseases. Edison began operations in July of 2006 with a clear mandate–expedite the translation of drugs with promising therapeutic potential into clinical development for inherited mitochondrial diseases. Two years later Edison’s first drug candidate EPI-A0001 is entering Phase 1 trials, and several promising candidates are in the pipeline. Edison is now leveraging its expertise in the mitochondria to tackle Huntington’s Disease and other conditions involving mitochondrial dysfunction, as well as defects in the generation and regulation of energy metabolism.
During working with Iterative Media Inc. this site was redeveloped. Originally site was done on top of FUSE framework, had administration backend. Complete structure redesign was needed and application, including administration backend, was completelly reworked. To save site administrators time, old UI was left. New XHTML design was intoduced as part of redesign process. Google Map and Google Custom Search integrated.
